17:25 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

EMA's CHMP on Sept. 21 recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam. CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta Therapeutics...
17:23 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 10 evaluable previously treated patients with PD-L1-negative non-small cell lung cancer (NSCLC) in the Phase II BGBC008 trial showing that bemcentinib (BGB324) plus Keytruda pembrolizumab led to a best...
19:34 , Sep 25, 2018 |  BC Extra  |  Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 10 evaluable previously treated patients with PD-L1-negative non-small cell lung cancer in the Phase II BGBC008 trial showing that bemcentinib (BGB324) plus Keytruda pembrolizumab led to a best overall...
21:45 , Sep 21, 2018 |  BC Extra  |  Company News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

EMA's CHMP Friday recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam. CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta Therapeutics (NASDAQ:SRPT) for...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Bavencio, Inlyta combo meets PFS endpoint in first-line RCC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab plus Inlyta axitinib met the primary endpoint of improving progression-free survival (PFS) vs. Sutent sunitinib in the Phase III JAVELIN Renal 101 trial to treat...
22:08 , Sep 11, 2018 |  BC Extra  |  Clinical News

Bavencio, Inlyta combo meets PFS endpoint in first-line RCC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab plus Inlyta axitinib met the primary endpoint of improving progression-free survival vs. Sutent sunitinib in the Phase III JAVELIN Renal 101 trial to treat previously...
17:54 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer In vitro, cell culture and mouse studies identified two benzenesulfonamide-based AXL inhibitors that could help treat breast cancer. Chemical synthesis and in vitro enzymatic activity assays of benzenesulfonamide analogs yielded two compounds that...
19:20 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

BerGenBio reports Phase Ib/II data for bemcentinib in melanoma

BerGenBio ASA (OSE:BGBIO) reported data from 19 patients with metastatic melanoma in a Phase Ib/II trial evaluating bemcentinib (BGB324) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) or Tafinlar dabrafenib/Mekinist trametinib from...
18:52 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

BerGenBio reports Phase II data for bemcentinib plus Keytruda in NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 15 evaluable patients with advanced non-small cell lung cancer (NSCLC) in the Phase II BGBC008 trial showing that once-daily 200 mg oral bemcentinib (BGB324) plus PD-1 inhibitor Keytruda pembrolizumab...
15:16 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Follow-on roundup: ImmunoGen, Mirati, Zymeworks, Viking, OptiNose

ImmunoGen Inc. (NASDAQ:IMGN), Mirati Therapeutics Inc. (NASDAQ:MRTX), Zymeworks Inc. (NYSE:ZYME; TSX:ZYME), Viking Therapeutics Inc. (NASDAQ:VKTX) and OptiNose Inc. (NASDAQ:OPTN) each priced follow-ons, raising a total of more than $465 million. ImmunoGen raised $150.7 million through the...